BRIEF-US SEC Ends Probe Of Trades Before Activision-Microsoft Merger With No Action

BRIEF-US SEC Ends Probe Of Trades Before Activision-Microsoft Merger With No Action - WSJ

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

BRIEF-US SEC Ends Probe Of Trades Before Activision-Microsoft Merger With No Action - WSJ

May 2, 2024 8:51 AM

May 2 (Reuters) -

* US SEC ENDS PROBE OF TRADES BEFORE ACTIVISION-MICROSOFT

MERGER

WITH NO ACTION - WSJ

Source text for Eikon: [https://tinyurl.com/3rb5yp5t]

Further company coverage:

Previous page： Google Cloud, Workday Collaborate on App Development With Generative AI Next page： Marriott International to Convert Three US Luxury Properties to Marriott Bonvoy Brands

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Google Cloud, Workday Collaborate on App Development With Generative AI

Jun 3, 2024

10:32 AM EDT, 06/03/2024 (MT Newswires) -- Alphabet's (GOOG, GOOGL) Google Cloud said Monday it expanded its partnership with Workday (WDAY) to improve how customers build and manage apps on Workday through new generative artificial intelligence capabilities. The partnership allows Workday to use Gemini models and Vertex AI to enable generative AI capabilities within Workday Extend, according to Google Cloud....

Marriott International to Convert Three US Luxury Properties to Marriott Bonvoy Brands

Jun 3, 2024

10:23 AM EDT, 06/03/2024 (MT Newswires) -- Marriott International ( MAR ) said Monday it intends to convert three luxury properties in the US to brands within its Marriott Bonvoy portfolio this summer. The conversions include The Resort at Pelican Hill in California, Turtle Bay Resort in Hawaii and a luxury hotel in New York City, the company said. Marriott...

Agios Says of Trial of Blood Disorder Drug Mitapivat Met Primary Endpoint; Shares Rise

Jun 3, 2024

10:28 AM EDT, 06/03/2024 (MT Newswires) -- Agios Pharmaceuticals ( AGIO ) said Monday a phase 3 trial of mitapivat in adults with transfusion-dependent thalassemia achieved its primary endpoint of transfusion reduction response. The study also achieved statistical significance for all key secondary endpoints assessing additional measures of decrease of transfusion burden compared with placebo, the company said. Agios said...

Moderna, Merck Reveal Three Year Data For Individualized Cancer Therapy In High-Risk Melanoma Patients

Jun 3, 2024

Monday, Moderna Inc ( MRNA ) and Merck & Co Inc ( MRK ) announced the first presentation of results from a planned analysis from the Phase 2b KEYNOTE-942/mRNA-4157-P201 study. The study is evaluating mRNA-4157 (V940), an investigational individualized neoantigen therapy (INT), in combination with Merck’s Keytruda in patients with resected high-risk melanoma (stage III/IV) following complete resection (n=157). With a...